JGC
AVIR icon

J. Goldman & Co’s Atea Pharmaceuticals AVIR Stock Holding History

J. Goldman & Co’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37,313
Closed -$801K – 352
2021
Q2 		$801K Buy
+37,313
New +$1.12M 0.03% 292

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

J. Goldman & Co's AVIR Position: Q3 2021 in Review

J. Goldman & Co sold out of Atea Pharmaceuticals (AVIR) in Q3 2021, closing a stake of 37,313 shares — an estimated $801K sold.

J. Goldman & Co first reported a position in AVIR in Q2 2021 and held it in 1 quarter. The position peaked at $801K in Q2 2021. 142 funds tracked by Wall St. Rank hold AVIR as of Q3 2021.

  • J. Goldman & Co reported no remaining Atea Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • J. Goldman & Co sold 37,313 Atea Pharmaceuticals shares in Q3 2021, an estimated $801K.
  • J. Goldman & Co first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • J. Goldman & Co's Atea Pharmaceuticals position peaked at $801K in Q2 2021.
  • 142 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2021.

Based on J. Goldman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.